PI3K抑制剂抗肿瘤临床研究进展  

Advances in the Clinical Development of PI3K Inhibitors as Anticancer Agents

作　　者：史鑫生 刘晓蓉 尤启冬[1] 

机构地区：[1]中国药科大学药学院,江苏南京210009 [2]南京圣和药业股份有限公司研发中心,江苏南京210038

出　　处：《药学进展》2017年第2期151-157,共7页Progress in Pharmaceutical Sciences

摘　　要：磷脂酰肌醇-3-激酶(PI3K)是一种胞内磷脂酰肌醇激酶,在介导细胞生长、发育、分裂、分化和凋亡等过程中发挥重要作用,因此PI3K抑制剂的开发已成为当前抗癌新药研究的热点之一。目前已有多个PI3K抑制剂进入临床研究阶段或已上市,其单用或与其他药物联用的疗效和安全性有待进一步临床验证。综述PI3K抑制剂作为抗肿瘤药物的临床研究进展,为其进一步研究与应用提供参考。Phosphatidylinositol 3-kinase（PI3K） is an intracellular phosphatidylinositol kinase and plays a very important role in the processes of cell growth, development, division, differentiation and apoptosis. Therefore, the development of PI3 K inhibitor for cancer chemotherapy is becoming a hot spot of present research. Currently, there are many PI3 K inhibitors under clinical development or approved for marketing. The efficacy and safety of PI3 K inhibitors as mono-therapy or in combined therapy still need further clinical evaluation. This paper reviewed the clinical development of phosphatidylinositol 3-kinase inhibitors as anticancer agents, so as to provide references for further investigation and application of PI3 K inhibitors.

关 键 词：PI3K PI3K抑制剂 抗肿瘤 临床研究 

分 类 号：R979.1[医药卫生—药品] R969.4[医药卫生—药学]